Welcome to our dedicated page for Metsera SEC filings (Ticker: MTSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metsera, Inc. (MTSR) SEC filings page provides access to the company’s regulatory history as a former Nasdaq-listed biotechnology issuer and documents its transition into a wholly owned subsidiary of Pfizer Inc. Metsera’s filings include multiple Forms 8-K detailing material events such as the signing and later amendment of the Agreement and Plan of Merger with Pfizer, the terms of unsolicited proposals from Novo Nordisk A/S, and the announcement of positive Phase 2b data for MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing in obesity.
Key filings for MTSR users include the September 21, 2025 and November 7, 2025 Forms 8-K describing the original and amended Pfizer merger agreements, including cash consideration and non-transferable contingent value rights (CVRs) tied to clinical and regulatory milestones for MET-097i and the MET-233i/MET-097i combination product. The November 13, 2025 Form 8-K reports completion of the merger, conversion of Metsera shares into cash plus CVRs, the resulting change in control, and the steps taken to delist MTSR from the Nasdaq Global Select Market and to deregister the common stock.
Additional 8-Ks capture Metsera’s responses to litigation initiated by Pfizer, the Board’s determinations that certain Novo Nordisk proposals constituted “Superior Company Proposals,” and detailed descriptions of proposed transaction structures, interim funding, non-voting convertible preferred stock, and alternative CVR terms. Other filings, such as the September 29, 2025 Form 8-K, furnish clinical data summaries for the VESPER-1 and VESPER-3 trials of MET-097i and outline the broader pipeline, including MET-233/097, MET-034/097, MET-097o, and MET-815.
On Stock Titan, these filings can be paired with AI-powered summaries that explain complex merger provisions, CVR mechanics, and clinical trial disclosures in plain language. Users can quickly see how each filing affected Metsera’s corporate status, from the initial merger announcement through shareholder approval, closing, and delisting. While MTSR no longer trades, its SEC filings remain a valuable resource for understanding the company’s development programs, transaction terms, and the regulatory steps associated with its acquisition by Pfizer.
Metsera, Inc. (MTSR) filed an 8‑K announcing it issued a statement in response to litigation filed by Pfizer. The statement is furnished as Exhibit 99.1. The filing’s forward‑looking section discusses Pfizer’s proposed acquisition of Metsera and notes risks tied to the litigation, including expenses, potential damages or other losses, and possible effects on Metsera’s business and stock price.
The disclosure also highlights conditions to closing the proposed acquisition, such as obtaining necessary regulatory approvals and the requisite stockholder vote, and acknowledges the possibility of competing offers, referencing Novo Nordisk A/S’s unsolicited proposal. Metsera has filed preliminary and definitive proxy statements related to the transaction, and the definitive proxy has been mailed to stockholders. Additional documents are available on the SEC’s website and Metsera’s site.
Metsera, Inc. filed an 8-K disclosing it issued a statement responding to litigation filed by Pfizer. The statement is furnished as Exhibit 99.1. The filing also reiterates extensive forward-looking statements tied to Pfizer’s proposed acquisition of Metsera, highlighting risks that include the litigation’s impact, regulatory approvals, the requisite stockholder vote, potential competing offers, integration uncertainties, transaction costs, market effects, and other external factors.
The company notes that a definitive proxy statement relating to the proposed transaction has been mailed to stockholders and that materials are available through the SEC and Metsera’s website. The filing clarifies it is not an offer or solicitation regarding any securities or votes.
Metsera (MTSR) announced its board has determined Novo Nordisk’s unsolicited proposal is a “Superior Company Proposal” under its existing Pfizer merger agreement. The Novo offer uses a two‑step structure: first, a Novo subsidiary would fund Metsera at $56.50 per common share, after which Metsera would declare a $56.50 per‑share cash dividend. In exchange, Metsera would issue Novo non‑voting convertible preferred stock representing 50% of fully diluted share capital on a post‑issuance basis.
In the second step, after required approvals and conditions, each common share would receive one CVR worth up to $21.25 in cash upon milestones: $4.75 for initiating the first Phase 3 of the MET‑233i/MET‑097i combo by December 31, 2027; $10.00 for U.S. FDA approval of the combo by December 31, 2031; and $6.50 for U.S. FDA approval of MET‑097i by December 31, 2029. Novo would also provide interim funding (PIK interest at 7% for certain amounts) convertible into the preferred at a $56.50 per‑share price, and pay the $190 million Pfizer termination fee upon termination of the Pfizer agreement. The Novo deal includes customary “no‑shop” and fiduciary‑out terms.
Metsera called a special meeting on November 13, 2025 to seek stockholder approval of its merger with Pfizer. Each share of Metsera common stock will be converted into the right to receive
The Board unanimously approved the merger, entered Voting and Support Agreements with major holders, and recommends voting FOR the merger and FOR the adjournment proposal. Approval requires a majority of outstanding shares as of the October 24, 2025 record date. As context, 105,292,746 shares were outstanding as of September 29, 2025, and directors and officers beneficially owned 40,541,829 shares (38.5%).
There is no financing condition. Required antitrust waiting periods under the HSR Act must expire or be terminated. A termination fee of
FMR LLC filed a Form 4 reporting insider changes in Metsera, Inc. (MTSR). On
Metsera, Inc. presents a preliminary proxy describing a proposed merger and the Board’s review of multiple acquisition proposals and financing scenarios. The document summarizes competing, non-binding offers ranging from a $2.0 billion cash proposal (price $21.13 per share) to Party 2 proposals valuing shares up to $95.00 (mix of stock and contingent value rights) and Pfizer proposals offering up to $65.00 per share including CVRs. Independent fairness analyses produced change-of-control reference values near $54.66–$54.76 per share. Key timeline items include an Initial Outside Date of March 21, 2026 (extendable to June 21, 2026) and planned HSR filings by November 3, 2025. The proxy details CVR structures tied to clinical milestones for MET-097i and MET-233i, potential budget adjustments tied to trial outcomes, executive make-whole caps of $47,000,000 (estimated $12.6M for the CEO) and modeled forecasts used by advisors.
Metsera, Inc. reported positive Phase 2b results for its obesity and metabolic candidate MET-097i, a first-in-class, fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing. In the VESPER-1 trial, MET-097i achieved mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses, showing substantial body-weight reduction versus placebo.
The company also reported strong tolerability from VESPER-1 and a planned interim tolerability analysis of VESPER-3. At the highest evaluated dose in VESPER-3, there was minimal diarrhea and a risk difference versus placebo of 13% for nausea and 11% for vomiting at 12 weeks after two titration steps, suggesting a potentially favorable side-effect profile for a GLP-1 therapy.
Based on these data, Metsera plans to start a global Phase 3 program for MET-097i in late 2025. Additional Phase 2b trials are underway to test a monthly dosing profile for long-term maintenance and use in people with type 2 diabetes, and MET-097i serves as the backbone for four more clinical programs in the company’s pipeline.
Metsera, Inc. disclosed a proposed merger with Pfizer Inc. under an Agreement and Plan of Merger dated September 21, 2025. The announced Merger Consideration includes a combination of cash and one contractual contingent value right (CVR) per share that may pay additional cash upon achievement of specified milestones under a CVR Agreement. Several related Voting and Support Agreements dated September 21, 2025 are filed among Pfizer, Metsera and certain ARCH and Validae investors. A Form of Letter Agreement and a Joint Press Release dated September 22, 2025 are included as exhibits. The filing notes the availability of the Company’s March 26, 2025 10-K and cautions that proxy and other documents to be filed with the SEC should be read when available for full details.
FMR LLC filed an amended Form 4 reporting an indirect acquisition of 1,107,547 shares of Metsera, Inc. (MTSR) on 09/02/2025, recorded under transaction code J and described as a distribution without payment of consideration. After the reported transaction, the filing shows 1,107,547 shares beneficially owned indirectly by persons and entities whose shares are subject to reporting by FMR LLC. The amendment corrects the previously reported number of indirectly acquired shares. The filing is signed on behalf of FMR LLC by Stephanie J. Brown and includes a remark that Abigail P. Johnson is a director, chair and CEO of FMR LLC and that members of the Johnson family hold the predominant Series B voting interest, participating in a shareholders' voting agreement.
FMR LLC and related entities reported multiple transactions in Metsera, Inc. (MTSR) common stock on 09/02/2025. The filing shows net disposals and acquisitions across affiliated vehicles: 1,350,000 shares were disposed (reported as a distribution) and several affiliated entities recorded both purchases and disposals, including acquisitions of 997,312 and 1,134,258 shares and smaller transfers of 20,250, 895 and 997 shares. One open-market sale by Impresa Fund IV LLC shows 268 shares sold at $36 per share. After the reported transactions, FMR-affiliated holders report beneficial ownership positions such as 3,189,540 shares held indirectly. The filing is signed by Stephanie J. Brown on behalf of FMR LLC and Abigail P. Johnson.